Sign up online today & collaborate
or click here to find out more
French drugmaker Sanofi is linking with Evotec to develop stem cell-based treatments for diabetes, under a deal that could earn the German biotech firm more than 300 million euros ($327 million).
Sanofi, a leading supplier of diabetes care, said on Friday the aim was develop beta cell-modulating diabetes therapies that could reduce or eliminate the need for insulin injections.
Beta cells play a key role in the development of diabetes and are destroyed by the patient's own immune system in type 1 diabetes.For more click here